Pinnacle Associates’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2025
Q2 | $4.15M | Sell |
114,268
-29,107
| -20% | -$1.06M | 0.06% | 265 |
|
2025
Q1 | $5.19M | Sell |
143,375
-5,118
| -3% | -$185K | 0.08% | 233 |
|
2024
Q4 | $6.25M | Buy |
148,493
+29,133
| +24% | +$1.23M | 0.08% | 211 |
|
2024
Q3 | $5.71M | Sell |
119,360
-41,660
| -26% | -$1.99M | 0.1% | 222 |
|
2024
Q2 | $6.62M | Buy |
161,020
+41,633
| +35% | +$1.71M | 0.1% | 202 |
|
2024
Q1 | $5.57M | Buy |
119,387
+27
| +0% | +$1.26K | 0.09% | 234 |
|
2023
Q4 | $5.71M | Buy |
119,360
+5
| +0% | +$239 | 0.1% | 225 |
|
2023
Q3 | $4.26M | Sell |
119,355
-3,841
| -3% | -$137K | 0.08% | 244 |
|
2023
Q2 | $5.68M | Sell |
123,196
-3,201
| -3% | -$148K | 0.1% | 217 |
|
2023
Q1 | $5.07M | Sell |
126,397
-2,039
| -2% | -$81.8K | 0.1% | 205 |
|
2022
Q4 | $5.95M | Sell |
128,436
-1,982
| -2% | -$91.8K | 0.13% | 183 |
|
2022
Q3 | $5.4M | Sell |
130,418
-3,640
| -3% | -$151K | 0.12% | 193 |
|
2022
Q2 | $8M | Sell |
134,058
-2,221
| -2% | -$133K | 0.17% | 147 |
|
2022
Q1 | $9.9M | Sell |
136,279
-5,295
| -4% | -$385K | 0.18% | 150 |
|
2021
Q4 | $11.9M | Sell |
141,574
-782
| -0.5% | -$65.8K | 0.21% | 132 |
|
2021
Q3 | $12.8M | Sell |
142,356
-4,159
| -3% | -$375K | 0.24% | 119 |
|
2021
Q2 | $14M | Buy |
146,515
+1,225
| +0.8% | +$117K | 0.25% | 115 |
|
2021
Q1 | $16.5M | Sell |
145,290
-13,065
| -8% | -$1.49M | 0.32% | 92 |
|
2020
Q4 | $21.9M | Sell |
158,355
-9,331
| -6% | -$1.29M | 0.45% | 66 |
|
2020
Q3 | $13.8M | Sell |
167,686
-6,513
| -4% | -$535K | 0.33% | 85 |
|
2020
Q2 | $13.6M | Sell |
174,199
-4,572
| -3% | -$358K | 0.34% | 85 |
|
2020
Q1 | $7.94M | Sell |
178,771
-33,616
| -16% | -$1.49M | 0.24% | 116 |
|
2019
Q4 | $9.07M | Buy |
212,387
+139,380
| +191% | +$5.95M | 0.2% | 137 |
|
2019
Q3 | $3.12M | Buy |
+73,007
| New | +$3.12M | 0.07% | 249 |
|